Navigation Links
Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
Date:3/19/2008

Acquires Rights from UCSD to Develop Cysteamine for the Treatment of NASH Enters Convivia(TM) Formulation and Manufacturing Agreement with Patheon

Pharmaceuticals

NOVATO, Calif., March 19 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego ("UCSD") around the use of Cysteamine, and Delayed Release Cysteamine ("DR Cysteamine") for the treatment of Non-alcoholic Steatohepatitis ("NASH"). In collaboration with doctors from UCSD School of Medicine, Bennu plans to initiate a Phase 2a clinical study of DR Cysteamine in NASH patients in 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

NASH is a form of progressive liver disease resulting from triglyceride fat accumulation in vacuoles of the liver cells, which causes decreased liver function and potentially leads to cirrhosis and liver failure. Cysteamine is currently approved by the FDA for the management of nephropathic cystinosis ("cystinosis"), a genetic lysosomal storage disease characterized by the poor transport of cystine out of lysosomes.

Ted Daley, President of Bennu stated, "We are delighted to extend our relationship with UCSD. Additional rights to Cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases. In addition to our ongoing clinical trial in cystinosis, we look forward to initiating a clinical trial of DR Cysteamine in NASH patients in 2008."

In a separate announcement, Raptor said that Bennu has entered into a formulation and manufacturing agreement for its Convivia(TM) product candidate with Patheon Pharmaceuticals
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
3. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
4. Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
5. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
11. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and FDA ... biosimilars. , Regulatory frameworks are evolving many countries to ... complex nature of biopharmaceuticals makes the demonstration of biosimilarity ... Based on the specific aspects of biosimilar drug development ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Pathwork Diagnostics, a,genomics-based diagnostics company focused on oncology, ... has initiated an,investigational study of the Pathwork(TM) Tissue ... to help determine a tumor,s origin so that,tissue-specific ... of the first,institutions in the country to evaluate ...
... Sensor for Airborne Biological Threats Receives Government ... ... 6 ICx Technologies, a developer of,advanced technology solutions for ... its AirSentinel(R) ambient aerosol,sensors for detection of airborne biological threats. ...
... Exchange Symbol: RVX, ORLANDO, FL, Nov. ... pleased to announce today key scientific data,was ... novel features of,RVX-208, at the American Heart ... of Compound RVX-208 Increases,Serum Levels of ApoA-I ...
Cached Biology Technology:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4ICx Awarded Department of Defense Contract for AirSentinel Monitors 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 2Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting 3
(Date:7/9/2014)... concern about the prevalence of antibiotic-resistant illness, Case ... pathway to disabling disease: blocking bacteria,s access to ... how bacterial siderophore, a small molecule, captures iron ... growth as well as how the body ... Their findings appear in a recent edition of ...
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Environmental and genetic factors influence a persons blood fat, ... disease (CAD). While there is some understanding of the ... defined. Now, in an international collaboration supported primarily by ... more than 25 genetic variants in 18 genes connected ...
... EVANSTON, Ill. --- Many researchers have tried to create a ... but most models have many different complicated factors, and no ... created a functional equation -- using only two parameters -- ... of Drosophila, better known as the fruit fly. They hope ...
... that facilitate the remarkably fast adaptation of intestinal bacteria ... issue of PLoS Genetics by researchers from INSERM and ... a simplified but ecologically relevant system the ... strain, Escherichia coli MG1655. E. coli is naturally resident ...
Cached Biology News:New genetic variants associated with lipid levels, risk for coronary artery disease 2New genetic variants associated with lipid levels, risk for coronary artery disease 3New genetic variants associated with lipid levels, risk for coronary artery disease 4New genetic variants associated with lipid levels, risk for coronary artery disease 5Researchers create mathematical model of fruit fly eyes 2Dissecting the genetic components of adaptation of E. coli to the mouse gut 2
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
... epitope specific for Nabeta2 is ... known proteins.,SPECIES REACTIVITIES: It ... human because the immunogen sequence ... Reactivity with other species has ...
Biology Products: